Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report.

ABSTRACT:

Background

In non-small cell lung cancer (NSCLC), ALK tyrosine kinase inhibitors (TKIs) have been associated with significant weight gain, predominantly in fat tissues. To date, only one case report has evaluated the impact of pharmacologic intervention on managing this drug-related side effect, with concerns about potential interactions with oncological treatments. No information is available regarding non-pharmacological intervention.

Case description

A 43-year-old man affected by metastatic ALK-rearranged NSCLC developed Grade 1 weight gain 1.5 months after starting Lorlatinib. The patient participated in a structured exercise program to manage this side effect. The program lasted 6 months and consisted of aerobic activities, including continuous and interval training, as

SUBMITTER: Ciurnelli C 

PROVIDER: S-EPMC12675186 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature